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OBJECTIVE — An International Expert Committee (IEC) and the American Diabetes Asso-
ciation(ADA)proposeddiagnosticcriteriafordiabetesandpre-diabetesbasedonA1Clevels.We
hypothesized that screening for diabetes and pre-diabetes with A1C measurements would differ
from using oral glucose tolerance tests (OGTT).
RESEARCH DESIGN AND METHODS — We compared pre-diabetes, dysglycemia
(diabetes or pre-diabetes), and diabetes identiﬁed by the proposed criteria (A1C 6.5% for
diabetes and 6.0–6.4% [IEC] or 5.7–6.4% [ADA] for high risk/pre-diabetes) with standard
OGTT diagnoses in three datasets. Non-Hispanic white or black adults without known diabetes
who had A1C and 75-g OGTT measurements were included from the prospective Screening for
Impaired Glucose Tolerance study (n  1,581), and from the National Health and Nutrition
Examination Survey (NHANES) III (n  2014), and NHANES 2005–2006 (n  1,111).
RESULTS — OGTTs revealed pre-diabetes in 35.8% and diabetes in 5.2% of combined study
subjects.A1Cprovidedreceiveroperatingcharacteristic(ROC)curveareasfordiabetesof0.79–
0.83, but ROC curve areas were 0.70 for dysglycemia or pre-diabetes. The proposed criteria
missed 70% of individuals with diabetes, 71–84% with dysglycemia, and 82–94% with pre-
diabetes. Compared with the IEC criteria, the ADA criteria for pre-diabetes resulted in fewer
false-negative and more false-positive result. There were also racial differences, with false-
positive results being more common in black subjects and false-negative results being more
common in white subjects. With use of NHANES 2005–2006 data, 5.9 million non-Hispanic
U.S.adultswithunrecognizeddiabetesand43–52millionwithpre-diabeteswouldbemissedby
screening with A1C.
CONCLUSIONS — The proposed A1C diagnostic criteria are insensitive and racially dis-
crepant for screening, missing most Americans with undiagnosed diabetes and pre-diabetes.
Diabetes Care 33:2184–2189, 2010
D
iabetes affects 21 million Ameri-
can adults (1,2), with a lifetime risk
rangingfrom20to50%,depend-
ing on sex and race (3). Identiﬁcation of
diabetes and its precursor, pre-diabetes,
can permit management to prevent com-
plications or delay progression from pre-
diabetes to diabetes. Because most U.S.
health care systems do not have system-
aticscreeningprograms,manyAmericans
have undiagnosed diabetes and pre-
diabetes,and,therefore,theseindividuals
are not initiating programs targeted at
prevention (2).
An International Expert Committee
(IEC) recently proposed new diagnostic
criteria based on measurement of A1C,
with A1C 6.5% for diabetes and 6.0–
6.4% for “high risk” of progression to di-
abetes (4). The American Diabetes
Association (ADA) subsequently pro-
posed A1C 6.5% for the diagnosis of
diabetes and 5.7–6.4% for the highest
risk to progress to diabetes (5).
Because A1C testing is readily avail-
able in the U.S., is relatively well stan-
dardized, exhibits low intraindividual
variation, and does not require fasting or
restriction to certain times of the day (6),
many clinicians might wish to use A1C
measurements to screen for diabetes and
pre-diabetes. However, the proposed di-
agnostic criteria were based largely on
identiﬁcationofdiabeticretinopathy,and
use of the proposed criteria as a screening
test is not understood. The IEC A1C
criteriahaverecentlybeencomparedwith
testingwithfastingglucoseororalglucose
tolerance tests (OGTTs) in various popu-
lations to diagnose diabetes (7–13) and
high-risk/pre-diabetes (10,11,13), but
the ADA A1C criteria have not been
studied.
WehypothesizedthatA1Cdiagnostic
criteria would fail to identify many sub-
jects with unrecognized diabetes or pre-
diabetes. We evaluated the proposed
criteria as screening tests in three popula-
tions,comparedwiththeOGTTasa“gold
standard”usedforidentiﬁcationofdiabe-
tes and pre-diabetes around the world
(14).
RESEARCH DESIGN AND
METHODS— We examined three
datasetsinwhichnon-Hispanicwhiteand
black adult subjects without known dia-
betes had both an OGTT and A1C mea-
sured (15).
In the Screening for Impaired Glu-
cose Tolerance (SIGT) study (16), health
care system employees and community
members in Atlanta were eligible if they
were aged 18 or above, were non-
Hispanicwhiteorblackrace,hadnoprior
diagnosis of diabetes, were not pregnant
or breastfeeding, were not taking glu-
cocorticoids, and were well enough to
work.Atotalof1,581subjectscompleted
the protocol.
The National Health and Nutrition
Examination Surveys (NHANES) as-
sessed adults and children across the U.S.
In NHANES III (17), 2,057 non-Hispanic
black or white subjects (to match the
SIGT study population) aged 40 years
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OGTT, meeting the inclusion criteria. In
NHANES 2005–2006 (18), 1,154 non-
Hispanic adult subjects aged 18 years
met the inclusion criteria. Age, BMI,
blood pressure, lipids, and family history
were categorized using conventional cri-
teria. After subjects with missing data
were excluded, there were 2,014 subjects
in NHANES III and 1,111 subjects in
NHANES 2005–2006, as described pre-
viously (15).
Glucose and A1C measurements
Plasma glucose and A1C measurements
have been described previously (16–18).
A1C measurements used NGSP–certiﬁed
systems (supplementary material, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0433/DC1).
Classiﬁcation of glucose tolerance
Glucose tolerance was classiﬁed by ADA
criteria on the basis of glucose levels in a
single75-gOGTT.Subjectsweregrouped
as normal glucose tolerance (fasting
plasma glucose [FPG] 100 mg/dl, with
2-h plasma glucose 140 mg/dl), pre-
diabetes (impaired fasting glucose with
FPG 100–125 mg/dl and 2-h plasma glu-
cose 200 mg/dl and/or impaired glu-
cose tolerance with FPG 126 mg/dl and
2-h plasma glucose 140–199 mg/dl), and
diabetes (FPG 126 mg/dl or 2-h plasma
glucose 200 mg/dl). The additional IEC
criteriaidentiﬁedsubjectsasnormal(A1C
6%), high risk for diabetes (A1C 6.0–
6.4%), and diabetes (A1C 6.5%),
whereas new ADA criteria identiﬁed sub-
jects as normal (A1C 5.7%), high risk
(A1C 5.7–6.4%), and diabetes (A1C
6.5%). Additional evaluations used
FPG 110 mg/dl for normal glucose tol-
erance. “Dysglycemia” includes pre-
diabetes or diabetes (OGTT) or high risk
or diabetes (A1C).
Statistical analysis
Means and frequencies were determined
in aggregate and by subgroup analysis of
the different glucose tolerance categories.
The discriminative effectiveness of
screeningwasevaluatedbytheareaunder
receiver operating characteristic (ROC)
curvesusingSAS9.2(SASInstitute,Cary,
NC) for the NHANES data and SPSS 15.0
(SPSS, Chicago, IL) for SIGT study data.
AllNHANESanalyseswereconductedus-
ingSAS9.2andSUDAANversion10(RTI
International, Research Triangle Park,
NC) to account for the complex survey
design. Prevalence estimates from
NHANES studies were weighted, except
where noted or when small sample sizes
made weighting estimates unstable; 95%
CIs were calculated using the Wilson
score method. Paired t tests compared
rates of apparent false-positive and false-
negative identiﬁcation of diabetes or high
risk in black and white subjects. Popula-
tion estimates were derived from the re-
sults of the weighted NHANES 2005–
2006datasetandappliedtonon-Hispanic
black or white adults for whom data were
available (156 million individuals). No
additional extrapolations were made.
RESULTS— As reported previously
(16), the 1,581 SIGT study subjects had
anaverageageof48yearsandBMIof30.3
kg/m
2; 42% were male, and 58% were
black. The 2,014 NHANES III subjects
had an average age of 55 years and BMI of
27.3 kg/m
2; 47% were male, and 10%
were black. The 1,111 NHANES 2005–
2006 subjects had an average age of 46
years and BMI of 28.5 kg/m
2; 49% were
male, and 13% were black (supplemen-
tary Tables 1A–1C, available in an online
appendix).
Using OGTT results, 5.8% of the
combined study subjects had new diabe-
tes, and 36% had pre-diabetes (Table 1).
Moreover,theproportionsweresimilarin
the three study populations: 4.6 and 33%
in the SIGT study (16), 7.6 and 38% in
NHANES III, and 5.2 and 36% in
NHANES 2005–2006 (supplementary
Tables 1A–1C). In contrast, assessment
by A1C was different from OGTT charac-
terization: 2.3% of combined subjects
were categorized as diabetes and 6.2%
were high risk by IEC criteria, whereas
2.3% were categorized as diabetes and
19.5% were high risk by ADA criteria.
Thethreepopulationswerecategorizedin
similar proportions by A1C with the IEC
and ADA criteria.
Thus, compared with an OGTT, A1C
testingresultedinmorenormaldiagnoses
(categorizations) and fewer high risk and
diabetes diagnoses with both the IEC and
ADA criteria. The ADA criteria resulted in
adistributionofdiagnosesmoresimilarto
those with the OGTT criteria by identify-
ing more subjects as high risk and fewer
subjectsasnormal.Thedifferentdistribu-
tionforOGTTversustheA1Ccriteriawas
seen in males, females, and non-Hispanic
whites but not in non-Hispanic blacks
(supplemental Tables 1A–1C), in whom
A1C diagnoses of diabetes and high risk
Table 1—Subjects identiﬁed by OGTT compared with A1C diagnoses
OGTT categories
A1C categories
IEC ADA
Normal
A1C 6.0%
High risk
A1C  6.0–6.4%
Diabetes
A1C 6.5%*
Normal
A1C 5.7%
High risk
A1C  5.7–6.4%
Diabetes
A1C 6.5%*
Row-wise %
NGT, 58  2.3% 97  0.90 2.5  0.80 0.29  0.12 88  3.0 12  2.9 0.29  0.12
Pre-diabetes, 36  1.4% 89  2.7 10  1.9 0.95  0.05 70  4.0 29  4.0 0.95  0.05
Diabetes, 5.8  0.9% 49  2.9 21  1.2 30  1.9 30  2.6 40  3.0 30  1.9
% of total
NGT 57  2.3 1.5  0.46 0.18  0.08 51  2.8 7.0  1.7 0.18  0.08
Pre-diabetes 32  1.7 3.5  0.59 0.35  0.03 25  2.1 10  1.2 0.35  0.03
Diabetes 2.8  0.53 1.2  0.15 1.7  0.28 1.8  0.44 2.3  0.25 1.7  0.28
Every subject was mapped according to an OGTT and A1C diagnostic criteria into 3  3 tables, and the percentage of the subjects within each dataset was
determined.NHANESvaluesarefromweightedestimates.ValueswerecombinedacrossthethreedatasetsandthemeanandSEMareshown.Eachvalueintheupper
rows is the mean and SEM of row-wise percentages, and percentage of subjects in each OGTT category is also included. The lower rows show the percentage of the
entire population. *Data in A1C categories for diabetes are the same for ADA and IEC diagnostic criteria.
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frequent.
A1C-based categorizations were
mostly incorrect for OGTT diagnoses of
both pre-diabetes and diabetes. Use of
both the ADA and the IEC criteria would
result in more false-positive and false-
negative categorizations than with the
OGTT (Table 2), generally more false-
negative than false-positive results. The
IECcriteriageneratedmorefalse-negative
and fewer false-positive results than the
ADA criteria. Incorrect identiﬁcations
across the three datasets averaged 90 and
71% for pre-diabetes (by IEC and ADA
criteria, respectively, combining false-
positive and false-negative results), 84
and 65% for dysglycemia (all false-
negative results), and 70% for diabetes
(all false-negative results). Extrapolating
the NHANES 2005–2006 ﬁndings to the
non-Hispanic American adult popula-
tion, A1C testing would incorrectly iden-
tify diabetes in 6.5 million (false-positive
and false-negative results). A1C testing
for pre-diabetes would also be incorrect
for 43 million Americans using the ADA
criteria and 52 million using the IEC cri-
teria,withthemajorityofthosebeingpre-
diabetic by an OGTT but normal by A1C
(Table 2). Importantly, the ADA criteria
wouldalsolabelnon-HispanicAmericans
with normal results on the OGTT (5.8
million as high risk and 75,000 as
diabetes).
ROC curve analyses were performed
to determine whether screening categori-
zationbyA1CversusOGTTwasindepen-
dent of cutoff values. ROC curve areas
were lowest for pre-diabetes and higher
for diabetes (Fig. 1). Only for diabetes
were areas under the ROC curve areas
0.80 (0.82 in the SIGT study, 0.80 in
NHANES III, and 0.83 in NHANES
2005–2006), whereas for pre-diabetes
they were lowest (0.65 in SIGT study,
0.62 in NHANES III, and 0.68 in
NHANES 2005–2006), and intermediate
for dysglycemia (0.67 in the SIGT study,
0.66 in NHANES III, and 0.70 in
NHANES 2005–2006).
To assess alternative cutoffs, we eval-
uated sensitivity, speciﬁcity, positive pre-
dictive value, and negative predictive
value for different A1C cutoffs across the
three datasets (supplementary Table 2,
available in an online appendix). Both the
IEC and the ADA criteria are speciﬁc for
diagnosing diabetes and pre-diabetes
(90% speciﬁcity above A1C cutoffs of
6.0%) but insensitive for both diabetes
(34% at A1C cutoff 6.5%) and pre-
diabetes (lowest with IEC criteria: 31%
above the cutoff of 5.7% and 13%
above the A1C cutoff of 6.0%). Approxi-
mately equal sensitivity and speciﬁcity
would be provided by cutoffs of 5.3–
5.5% for pre-diabetes or dysglycemia and
of 5.5–5.8% for diabetes. The sum of sen-
sitivity and speciﬁcity was maximized at
5.4–5.6% for pre-diabetes, 5.5–5.6% for
dysglycemia, and 5.7–5.9% for diabetes.
However, even cutoffs maximizing
the sum of sensitivity and speciﬁcity for
the NHANES 2005–2006 dataset (A1C
5.4% for high risk and 5.7% for diabetes)
would incorrectly identify diabetes in
21 million (19 million false-positive re-
sults and 2.2 million false-negative re-
sults) and incorrectly identify high risk in
59 million non-Hispanic American
adults, with fewer false-positive results
but more false-positive results at these
lower cutoffs.
Repeating the above analyses with a
higher fasting plasma glucose cutoff for
normalglucosetolerance(FPG110mg/
dl)didnotchangetheresults(seesupple-
Table 2—Rates of correct and incorrect classiﬁcation
OGTT criteria IEC criteria ADA criteria
Normal (%)
% correct 97  0.90 88  3.0
FP high risk 2.5  0.79 12  2.9
FP diabetes 0.30  0.12 0.30  0.12
Pre-diabetes (%)
% correct 10  1.9 29  4.0
FN normal 89  1.9 70  4.1
FP diabetes 0.97  0.04 0.97  0.04
Dysglycemia (%)
% correct 16  2.0 35  3.5
FN normal 84  2.0 65  3.5
Diabetes (%)
% correct 30  1.9 30  1.9
FN normal 49  2.9 30  2.6
FN high risk 21  1.2 40  3.0
Correct or incorrect classiﬁcation within each diagnostic category was evaluated in each dataset, and the
average  SEM of the rates across the three datasets is listed. % correct is the proportion of subjects with a
given OGTT diagnostic criterion who were correctly identiﬁed by A1C diagnostic criteria. Incorrect diag-
noses were false positive (FP) and false negative (FN), which were further categorized as being incorrectly
normal, high risk, or diabetes per A1C testing. SIGT study proportions were calculated from raw data;
NHANES proportions were calculated from weighted estimates.
Figure 1—ROC curve analyses for each of the
threedatasets,showingA1Cscreeningtodetect
pre-diabetes, dysglycemia, and diabetes. A:
Pre-diabetes. B: Dysglycemia. C: Diabetes. F,
0.5% intervals of A1C; E, ADA and IEC cutoff
for diabetes at A1C  6.5%;  , ADA cutoff for
highriskatA1C5.7%;f,IECcutoffforhigh
risk at A1C  6.0%. Points are labeled with
A1C values.       , SIGT study; – – –,
NHANES III; ——, NHANES 2005–2006.
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supplementary Fig. 1, available in an on-
line appendix).
In addition, the impact of the A1C-
basedcriteriadiffersbyrace.Therewould
be more false-negative results and fewer
false-positive results (Fig. 2) in non-
Hispanicwhitesthanblackswithboththe
IEC and ADA criteria (P  0.05 for both).
Of those with diabetes by OGTT, 78% of
whites vs. 51% of blacks would have
false-negative results (P  0.01), whereas
0.3%ofwhitesvs.1.8%ofblackswithout
diabetes would have false-positive results
(P  0.15). With the IEC criteria for high
risk,94%ofwhitesvs.77%ofblackswith
pre-diabetes by OGTT would have false-
negative results, whereas 1.7% of
whites vs. 9.0% of blacks without pre-
diabetes would have false-positive re-
sults (P  0.02 that whites have more
false-negative and less false-positive re-
sults). At the lower ADA cutoff for
high risk, there would be fewer false-
negative but more false-positive results:
78%ofwhitesvs.56%ofblackswithpre-
diabetes by OGTT would have false-
negative results, whereas 8.5% of whites
vs. 18% of blacks without pre-diabetes
would have false-positive results (P 
0.05 that whites have more false-negative
than false-positive results). However, the
percentage of incorrectly identiﬁed high-
risk subjects (false-negative plus false-
positive results) with A1C screening for
pre-diabetes was lower with the ADA cri-
teria: 96% of whites and 86% of blacks
with the IEC criteria vs. 87% of whites
and 73% of blacks with the ADA criteria.
With extrapolation from the
NHANES 2005–2006 dataset, A1C
screening with the IEC and ADA criteria
would incorrectly identify diabetes (false-
positive or false-negative results) in
470,000 black and 6 million white non-
Hispanic Americans. The IEC criteria
would incorrectly identify high risk in 6
million black and 42 million white non-
HispanicAmericans.Althoughtherewould
befewermissedsubjectsusingtheADAcri-
teria, potentially incorrect diagnoses would
only be reduced for non-Hispanic black
adults, incorrectly identifying high risk in 4
million black but 47 million white non-
Hispanic Americans.
CONCLUSIONS— Our analyses
demonstrate that the IEC and ADA A1C
diagnosticcriteriahavelimitationsforuse
in screening, which include 1) high spec-
iﬁcity but low sensitivity, 2) intrinsic in-
accuracy even with alternative cutoffs,
and 3) discrepant application to different
racial groups. The results are consistent
with two different methodologies for
measurement of A1C (immunoassay in
the SIGT study and high-performance liq-
uid chromatography in NHANES) and
with one dataset including black and white
volunteers(theSIGTstudy)andtwoothers
representative of the non-Hispanic Amer-
ican population (NHANES III and
NHANES 2005–2006). Although our
ﬁndings support diagnosing diabetes by
the proposed A1C criteria as rarely false
positive, use of the proposed criteria
would not be a good screening strategy to
identify the many Americans who cur-
rently have unrecognized diabetes or pre-
diabetes as found with OGTTs, a
diagnostic standard currently used
around the world.
Although the IEC and ADA did not
recommend use of their criteria for
screening, A1C testing has attractive fea-
tures, including simplicity, standardiza-
tion, availability, low day-to-day
variability, and lack of need for prior fast-
ing or restriction in time of measurement,
and A1C is widely used as an indicator of
diabetes control. In addition, the IEC
stated that A1C “may be better” than gly-
cemic criteria for diagnosing diabetes (4),
and the ADA listed the A1C criteria
“above” the glycemic criteria (5). How-
ever, other workers have questioned the
use of A1C measurements for diagnosis
(6,19). Several groups have now applied
the proposed IEC criteria to a variety of
datasets. The IEC criteria would miss di-
agnosesofdiabetesandpre-diabetesinan
older, predominantly white American
population (8), and in another NHANES
populationwithmeasurementofFPGbut
noOGTTs(7),andROCcurveareas,sen-
sitivity and speciﬁcity were similar to
those in the current study with an Amer-
ican population enriched in Hispanic
adults (12). There was greater variability
in the international studies (9–11,13),
possiblyreﬂectingethnicandracialdiffer-
ences as well as differences in the under-
lying rates of undiagnosed diabetes
(9,11). None of the studies found the IEC
high-risk criteria to be similar to pre-
diabetes with OGTTs (10,11,13).
It is beyond our analysis to address
the accuracy of OGTT versus A1C, but
theydifferintrinsically.A1Cwithinanin-
dividual ﬂuctuates little from day to day,
whereas an OGTT can reﬂect day-to-day
differences in insulin secretion and insu-
lin action. As such, A1C should better as-
sess glycemic trends over several months,
whereas an OGTT should better assess im-
mediate glucose homeostasis. Moreover,
thereissubstantialinterindividualvariation
in A1C at the same levels of glycemia
(20,21), reﬂecting differences in red cell
penetration,glycation,hemoglobinspecies,
red cell half-life, vitamin and medication
status, and others factors (22). Such varia-
tion would be expected to make it more
difﬁcult for A1C measurements to distin-
guish small differences in glycemia, e.g.,
pre-diabetes versus normal.
Our ﬁndings that the proposed A1C
criteria result in more false-positive and
fewerfalse-negativeresultsinblackscom-
paredwithwhitesareconsistentwithpre-
viousreportsthatatsimilarglucoselevels,
A1C levels are higher in blacks than
whites (23). This ﬁnding explains both
relative underdiagnosis in whites and
overdiagnosis in blacks. The basis for
such differences remains unknown.
Figure2—Ratesoffalse-positiveandfalse-negativeA1CscreeningcomparedwithOGTTscreen-
ingaccordingtoraceacrossthethreestudypopulations. ,non-Hispanicwhites;f,non-Hispanic
blacks.Theratesofsubjectswithfalse-positive(FP)andfalse-negative(FN)resultsforblackand
white subgroups across the populations are shown as mean  SEM.
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sessments in 4,500 subjects, similarity
of ﬁndings across multiple datasets with
different A1C methodologies, evaluation
of both IEC and ADA criteria, compari-
sonofthegeneralutilityofA1Cscreening
with the speciﬁc problems of the pro-
posed criteria, and the identiﬁcation of
potential problems in applications to dif-
ferent racial/ethnic groups. One limita-
tion is performance of only a single
OGTT,butsuchanapproachreﬂectsclin-
ical practice. Moreover, abnormal results
on a single OGTT was highly predictive of
subsequent diabetes in Pima Indians (24),
and differences found on repeat studies
should be included in the variability of the
ROCcurveanalyses.Wealsodidnotsearch
for factors that can be problematic for A1C
measurements, such as hemoglobinopa-
thies and anemia. Further studies would be
required before our ﬁndings with the ADA
criteria could be generalized to other racial/
ethnic groups, but problems with the IEC
criteria have been reported with diverse
populations (8,9,12).
Although A1C screening may be of
limited value, better test characteristics
appear to be provided by measuring ran-
dom plasma glucose (25) or glucose 1 h
after a 50-g oral glucose challenge (16);
either could be obtained opportunisti-
cally during ofﬁce visits, at any time of
day, and without a prior fast. Other tests
or combinations of tests may also be use-
ful, and it is possible that health econom-
icsanalyseswouldidentifyoneoranother
test as being more cost-effective in differ-
ent patient populations and clinical set-
tings. We still need to identify previously
unrecognized diabetes and pre-diabetes
to initiate preventive management.
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